CN1260221C - 一种铂(ⅱ)类金属配合物依铂的制备方法 - Google Patents
一种铂(ⅱ)类金属配合物依铂的制备方法 Download PDFInfo
- Publication number
- CN1260221C CN1260221C CN 200410014772 CN200410014772A CN1260221C CN 1260221 C CN1260221 C CN 1260221C CN 200410014772 CN200410014772 CN 200410014772 CN 200410014772 A CN200410014772 A CN 200410014772A CN 1260221 C CN1260221 C CN 1260221C
- Authority
- CN
- China
- Prior art keywords
- formula
- platinum
- reaction
- water
- representative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- HRGDZIGMBDGFTC-UHFFFAOYSA-N platinum(2+) Chemical compound [Pt+2] HRGDZIGMBDGFTC-UHFFFAOYSA-N 0.000 title claims abstract description 33
- 238000000034 method Methods 0.000 title claims description 24
- XJXKGUZINMNEDK-GPJOBVNKSA-L [(4r,5r)-5-(aminomethyl)-2-propan-2-yl-1,3-dioxolan-4-yl]methanamine;platinum(2+);propanedioate Chemical compound [Pt+2].[O-]C(=O)CC([O-])=O.CC(C)C1O[C@H](CN)[C@@H](CN)O1 XJXKGUZINMNEDK-GPJOBVNKSA-L 0.000 title abstract description 5
- 229950006835 eptaplatin Drugs 0.000 title abstract description 5
- 150000004696 coordination complex Chemical class 0.000 title 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims abstract description 72
- 229910052697 platinum Inorganic materials 0.000 claims abstract description 34
- 238000002360 preparation method Methods 0.000 claims abstract description 14
- NMPWOSFVNNNGHW-UHFFFAOYSA-N [Hg].C(CC(=O)O)(=O)O Chemical compound [Hg].C(CC(=O)O)(=O)O NMPWOSFVNNNGHW-UHFFFAOYSA-N 0.000 claims abstract description 6
- 238000006243 chemical reaction Methods 0.000 claims description 24
- 229910052751 metal Inorganic materials 0.000 claims description 19
- 239000002184 metal Substances 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 14
- 239000003999 initiator Substances 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 4
- 239000012736 aqueous medium Substances 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 3
- 239000002609 medium Substances 0.000 claims description 3
- 230000035484 reaction time Effects 0.000 claims description 3
- 239000012046 mixed solvent Substances 0.000 claims description 2
- 239000012429 reaction media Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 abstract description 7
- 238000000926 separation method Methods 0.000 abstract description 4
- 239000003005 anticarcinogenic agent Substances 0.000 abstract 1
- 150000004985 diamines Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000047 product Substances 0.000 description 19
- 239000000706 filtrate Substances 0.000 description 17
- 238000003756 stirring Methods 0.000 description 13
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 10
- 239000007864 aqueous solution Substances 0.000 description 10
- HCPOCMMGKBZWSJ-UHFFFAOYSA-N ethyl 3-hydrazinyl-3-oxopropanoate Chemical compound CCOC(=O)CC(=O)NN HCPOCMMGKBZWSJ-UHFFFAOYSA-N 0.000 description 10
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- 238000001035 drying Methods 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 230000006837 decompression Effects 0.000 description 8
- BQPIGGFYSBELGY-UHFFFAOYSA-N mercury(2+) Chemical compound [Hg+2] BQPIGGFYSBELGY-UHFFFAOYSA-N 0.000 description 8
- 238000001556 precipitation Methods 0.000 description 8
- XKTYXVDYIKIYJP-UHFFFAOYSA-N 3h-dioxole Chemical compound C1OOC=C1 XKTYXVDYIKIYJP-UHFFFAOYSA-N 0.000 description 7
- 238000010268 HPLC based assay Methods 0.000 description 7
- -1 platinum series compounds Chemical class 0.000 description 7
- 239000013078 crystal Substances 0.000 description 6
- NDKKKEPYKOOXLG-UHFFFAOYSA-L mercury(1+);diiodide Chemical compound [Hg]I.[Hg]I NDKKKEPYKOOXLG-UHFFFAOYSA-L 0.000 description 6
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Substances [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 5
- 229910052709 silver Inorganic materials 0.000 description 5
- 239000004332 silver Substances 0.000 description 5
- LVRUOWWENCLMAU-UHFFFAOYSA-L 1,3-dioxa-2-mercuracyclohexane-4,6-dione Chemical compound C1C(=O)O[Hg]OC1=O LVRUOWWENCLMAU-UHFFFAOYSA-L 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000003957 anion exchange resin Substances 0.000 description 3
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 3
- 229960004562 carboplatin Drugs 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229910021645 metal ion Inorganic materials 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- BGARROUSYWXSED-UHFFFAOYSA-N dimercury(2+) Chemical compound [Hg+][Hg+] BGARROUSYWXSED-UHFFFAOYSA-N 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- QKEOZZYXWAIQFO-UHFFFAOYSA-M mercury(1+);iodide Chemical compound [Hg]I QKEOZZYXWAIQFO-UHFFFAOYSA-M 0.000 description 2
- UKWHYYKOEPRTIC-UHFFFAOYSA-N mercury(II) oxide Inorganic materials [Hg]=O UKWHYYKOEPRTIC-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229960001756 oxaliplatin Drugs 0.000 description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 201000000498 stomach carcinoma Diseases 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- HEYGYQDRKHISNT-UHFFFAOYSA-N azane;propanedioic acid Chemical compound N.OC(=O)CC(O)=O HEYGYQDRKHISNT-UHFFFAOYSA-N 0.000 description 1
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- LGQRIMRZKJJQTC-UHFFFAOYSA-L disilver;propanedioate Chemical compound [Ag+].[Ag+].[O-]C(=O)CC([O-])=O LGQRIMRZKJJQTC-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 150000002730 mercury Chemical class 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 229950007221 nedaplatin Drugs 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- LULRWFILUQGIDA-UHFFFAOYSA-N platinum;propanedioic acid Chemical compound [Pt].OC(=O)CC(O)=O LULRWFILUQGIDA-UHFFFAOYSA-N 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 235000007715 potassium iodide Nutrition 0.000 description 1
- 229960004839 potassium iodide Drugs 0.000 description 1
- WLNXUYIIBVRGBH-UHFFFAOYSA-N potassium;propanedioic acid Chemical compound [K].OC(=O)CC(O)=O WLNXUYIIBVRGBH-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- PRWXGRGLHYDWPS-UHFFFAOYSA-L sodium malonate Chemical compound [Na+].[Na+].[O-]C(=O)CC([O-])=O PRWXGRGLHYDWPS-UHFFFAOYSA-L 0.000 description 1
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410014772 CN1260221C (zh) | 2004-04-28 | 2004-04-28 | 一种铂(ⅱ)类金属配合物依铂的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410014772 CN1260221C (zh) | 2004-04-28 | 2004-04-28 | 一种铂(ⅱ)类金属配合物依铂的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1569863A CN1569863A (zh) | 2005-01-26 |
CN1260221C true CN1260221C (zh) | 2006-06-21 |
Family
ID=34478590
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200410014772 Expired - Fee Related CN1260221C (zh) | 2004-04-28 | 2004-04-28 | 一种铂(ⅱ)类金属配合物依铂的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1260221C (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100497359C (zh) * | 2006-01-06 | 2009-06-10 | 昆明贵研药业有限公司 | 抗癌药舒铂的一种新合成工艺 |
-
2004
- 2004-04-28 CN CN 200410014772 patent/CN1260221C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1569863A (zh) | 2005-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107286199B (zh) | 一种双核芳基钌金属配合物及其合成方法和应用 | |
CN103467528A (zh) | 一种洛铂的制备方法 | |
CN100408588C (zh) | 具有低含量伴生杂质的奥沙利铂及其制备方法 | |
CN101402655A (zh) | 一种米铂的制备方法 | |
CN101830933B (zh) | 一种合成抗肿瘤药物米铂的方法 | |
CN1260221C (zh) | 一种铂(ⅱ)类金属配合物依铂的制备方法 | |
CN103214525A (zh) | 1,2-二氨基环己烷-铂(ii)-络合物的制取方法 | |
JP2010042403A (ja) | 水の浄化方法 | |
CN101918379B (zh) | 铂配位化合物及其利用 | |
CN101723988A (zh) | 一种杂质含量极低的奥沙利铂的制备方法 | |
CN101891771B (zh) | 一种制备奥沙利铂的方法 | |
CN101012244A (zh) | 一种含银量极低的奈达铂的制备方法 | |
CN111808141B (zh) | 一种高效制备洛铂无水物的方法 | |
CN106883251A (zh) | 一种氨基酸多吡啶铜配合物及其制备方法和应用 | |
CN100582115C (zh) | 一种合成抗肿瘤药物卡铂的方法 | |
CN101234788A (zh) | 一种合成抗肿瘤药物顺铂的新方法 | |
CN101775040B (zh) | 吡铂的制备方法 | |
JP2007512318A (ja) | 白金(ii)錯体並びに該錯体の製法及び使用 | |
RU2457838C1 (ru) | Способ получения транс-1,2-диаминциклогексантетрахлороплатины (iv) | |
CN101302236A (zh) | 一种合成抗肿瘤药物奈达铂的新方法 | |
CN101475599B (zh) | 一种合成抗肿瘤药物奈达铂的方法 | |
CN1152036C (zh) | 制备铂(ⅱ)配合物的一种方法 | |
CN101343291B (zh) | 奥沙利铂的制备方法 | |
EP2208731B1 (en) | Process for preparation of 1,2-diamino-cyclohexane-platinum(II) complexes | |
CN101027313A (zh) | 顺式-二碘·(反式-l-1,2-环己二胺)合铂(ⅱ)配合物以及制备高纯度奥沙利铂的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: JIANGSU D+R PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: NANJING KEYUAN MEDICINAL TECHNOLOGY CO., LTD. Effective date: 20120627 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 210009 NANJING, JIANGSU PROVINCE TO: 225300 TAIZHOU, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20120627 Address after: 225300, G38, 1 drug City Avenue, Jiangsu, Taizhou Patentee after: JIANGSU D&R PHARMACEUTICAL CO., LTD. Address before: 410, room 139, 210009 Ma Tai Street, Jiangsu, Nanjing Patentee before: Nanjing Keyuan Medicinal Technology Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060621 Termination date: 20180428 |
|
CF01 | Termination of patent right due to non-payment of annual fee |